News >

INO-5401/INO-9012 Plus Cemiplimab Hits High 6-Month PFS Rate in Newly Diagnosed GBM

Gina Columbus @ginacolumbusonc
Published: Tuesday, Nov 05, 2019

David Reardon, MD, clinical director for Neuro-Oncology of Dana-Farber Cancer Institute

David Reardon, MD

The combination of INO-5401 and INO-9012 with cemiplimab (Libtayo), plus chemoradiation, demonstrated promising 6-month progression-free survival (PFS) rates in patients with newly diagnosed glioblastoma multiforme (GBM) that is O6-methylguanine-DNA methyltransferase (MGMT) methylated or unmethylated, according to interim findings of a phase II trial (NCT03491683).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x